Human Tetherin Exerts Strong Selection Pressure on the HIV-1 Group N Vpu Protein

HIV-1 groups M and N emerged within the last century following two independent cross-species transmissions of SIVcpz from chimpanzees to humans. In contrast to pandemic group M strains, HIV-1 group N viruses are exceedingly rare, with only about a dozen infections identified, all but one in individuals from Cameroon. Poor adaptation to the human host may be responsible for this limited spread of HIV-1 group N in the human population. Here, we analyzed the function of Vpu proteins from seven group N strains from Cameroon, the place where this zoonosis originally emerged. We found that these N-Vpus acquired four amino acid substitutions (E15A, V19A and IV25/26LL) in their transmembrane domain (TMD) that allow efficient interaction with human tetherin. However, despite these adaptive changes, most N-Vpus still antagonize human tetherin only poorly and fail to down-modulate CD4, the natural killer (NK) cell ligand NTB-A as well as the lipid-antigen presenting protein CD1d. These functional deficiencies were mapped to amino acid changes in the cytoplasmic domain that disrupt putative adaptor protein binding sites and an otherwise highly conserved ßTrCP-binding DSGxxS motif. As a consequence, N-Vpus exhibited aberrant intracellular localization and/or failed to recruit the ubiquitin-ligase complex to induce tetherin degradation. The only exception was the Vpu of a group N strain recently discovered in France, but originally acquired in Togo, which contained intact cytoplasmic motifs and counteracted tetherin as effectively as the Vpus of pandemic HIV-1 M strains. These results indicate that HIV-1 group N Vpu is under strong host-specific selection pressure and that the acquisition of effective tetherin antagonism may lead to the emergence of viral variants with increased transmission fitness.

[1]  Lamar B. Fleming,et al.  Vpu-Deficient HIV Strains Stimulate Innate Immune Signaling Responses in Target Cells , 2012, Journal of Virology.

[2]  M. McElrath,et al.  Vpu Mediates Depletion of Interferon Regulatory Factor 3 during HIV Infection by a Lysosome-Dependent Mechanism , 2012, Journal of Virology.

[3]  S. Neil,et al.  A Cytoplasmic Tail Determinant in HIV-1 Vpu Mediates Targeting of Tetherin for Endosomal Degradation and Counteracts Interferon-Induced Restriction , 2012, PLoS pathogens.

[4]  F. Kirchhoff,et al.  HIV-1 Group P is unable to antagonize human tetherin by Vpu, Env or Nef , 2011, Retrovirology.

[5]  G. Towers,et al.  Analysis of the human immunodeficiency virus type 1 M group Vpu domains involved in antagonizing tetherin , 2011, The Journal of general virology.

[6]  C. Delaugerre,et al.  HIV-1 group N: travelling beyond Cameroon , 2011, The Lancet.

[7]  P. Cannon,et al.  Lack of adaptation to human tetherin in HIV-1 Group O and P , 2011, Retrovirology.

[8]  S. Neil,et al.  Separable Determinants of Subcellular Localization and Interaction Account for the Inability of Group O HIV-1 Vpu To Counteract Tetherin , 2011, Journal of Virology.

[9]  J. Fritz,et al.  HIV-1 Vpu Blocks Recycling and Biosynthetic Transport of the Intrinsic Immunity Factor CD317/Tetherin To Overcome the Virion Release Restriction , 2011, mBio.

[10]  L. Montaner,et al.  Evidence for the innate immune response as a correlate of protection in human immunodeficiency virus (HIV)‐1 highly exposed seronegative subjects (HESN) , 2011, Clinical and experimental immunology.

[11]  J. Fritz,et al.  β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release , 2011, Retrovirology.

[12]  E. Campbell,et al.  Degranulation of natural killer cells following interaction with HIV-1-infected cells is hindered by downmodulation of NTB-A by Vpu. , 2010, Cell host & microbe.

[13]  C. Brennan,et al.  Confirmation of Putative HIV-1 Group P in Cameroon , 2010, Journal of Virology.

[14]  Takeshi Yoshida,et al.  Identification of Amino Acids in the Human Tetherin Transmembrane Domain Responsible for HIV-1 Vpu Interaction and Susceptibility , 2010, Journal of Virology.

[15]  S. Neil,et al.  Determinants of Tetherin Antagonism in the Transmembrane Domain of the Human Immunodeficiency Virus Type 1 Vpu Protein , 2010, Journal of Virology.

[16]  K. Strebel,et al.  HIV-1 Vpu targets cell surface markers CD4 and BST-2 through distinct mechanisms. , 2010, Molecular aspects of medicine.

[17]  Mustapha Samrakandi,et al.  Dual-color click beetle luciferase heteroprotein fragment complementation assays. , 2010, Chemistry & biology.

[18]  M. Moll,et al.  Inhibition of lipid antigen presentation in dendritic cells by HIV-1 Vpu interference with CD1d recycling from endosomal compartments. , 2010, Blood.

[19]  Rajendra Singh,et al.  BST-2/tetherin: a new component of the innate immune response to enveloped viruses. , 2010, Trends in microbiology.

[20]  P. Sharp,et al.  The evolution of HIV-1 and the origin of AIDS , 2010, Philosophical Transactions of the Royal Society B: Biological Sciences.

[21]  F. Kirchhoff Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses. , 2010, Cell host & microbe.

[22]  Michael Emerman,et al.  Ancient Adaptive Evolution of Tetherin Shaped the Functions of Vpu and Nef in Human Immunodeficiency Virus and Primate Lentiviruses , 2010, Journal of Virology.

[23]  F. Kirchhoff,et al.  Tetherin: Holding On and Letting Go , 2010, Cell.

[24]  Andrew A McCarthy,et al.  Structural basis of HIV-1 tethering to membranes by the BST-2/tetherin ectodomain. , 2010, Cell host & microbe.

[25]  É. Cohen,et al.  Antagonism of Tetherin Restriction of HIV-1 Release by Vpu Involves Binding and Sequestration of the Restriction Factor in a Perinuclear Compartment , 2010, PLoS pathogens.

[26]  O. Gascuel,et al.  New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. , 2010, Systematic biology.

[27]  P. Cannon,et al.  Anti-tetherin activities in Vpu-expressing primate lentiviruses , 2010, Retrovirology.

[28]  C. McArthur,et al.  Four new HIV-1 group N isolates from Cameroon: Prevalence continues to be low. , 2010, AIDS research and human retroviruses.

[29]  F. Kirchhoff,et al.  Vpu serine 52 dependent counteraction of tetherin is required for HIV-1 replication in macrophages, but not in ex vivo human lymphoid tissue , 2010, Retrovirology.

[30]  Ravindra K. Gupta,et al.  A tail of Tetherin: how pandemic HIV-1 conquered the world. , 2009, Cell host & microbe.

[31]  G. Learn,et al.  Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. , 2009, Cell host & microbe.

[32]  Marc C. Johnson,et al.  Tetherin Inhibits HIV-1 Release by Directly Tethering Virions to Cells , 2009, Cell.

[33]  Jean-Yves Nau,et al.  [A new human immunodeficiency virus derived from gorillas]. , 2009, Revue medicale suisse.

[34]  J. Luban,et al.  HIV-1 Vpu Neutralizes the Antiviral Factor Tetherin/BST-2 by Binding It and Directing Its Beta-TrCP2-Dependent Degradation , 2009, PLoS pathogens.

[35]  Marc C. Johnson,et al.  Nef proteins from simian immunodeficiency viruses are tetherin antagonists. , 2009, Cell host & microbe.

[36]  A. Moses,et al.  Vpu Directs the Degradation of the Human Immunodeficiency Virus Restriction Factor BST-2/Tetherin via a βTrCP-Dependent Mechanism , 2009, Journal of Virology.

[37]  R. Benarous,et al.  Vpu Antagonizes BST-2–Mediated Restriction of HIV-1 Release via β-TrCP and Endo-Lysosomal Trafficking , 2009, PLoS pathogens.

[38]  S. Westmoreland,et al.  Species-Specific Activity of SIV Nef and HIV-1 Vpu in Overcoming Restriction by Tetherin/BST2 , 2009, PLoS pathogens.

[39]  D. Pillay,et al.  Mutation of a Single Residue Renders Human Tetherin Resistant to HIV-1 Vpu-Mediated Depletion , 2009, PLoS pathogens.

[40]  P. Bieniasz,et al.  Species-Specific Activity of HIV-1 Vpu and Positive Selection of Tetherin Transmembrane Domain Variants , 2009, PLoS pathogens.

[41]  Michael Emerman,et al.  HIV-1 accessory proteins--ensuring viral survival in a hostile environment. , 2008, Cell host & microbe.

[42]  Marc C. Johnson,et al.  The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. , 2008, Cell host & microbe.

[43]  P. Bieniasz,et al.  Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu , 2008, Nature.

[44]  Rodrigo Lopez,et al.  Clustal W and Clustal X version 2.0 , 2007, Bioinform..

[45]  F. Kirchhoff,et al.  Nef-Mediated Enhancement of Virion Infectivity and Stimulation of Viral Replication Are Fundamental Properties of Primate Lentiviruses , 2007, Journal of Virology.

[46]  L. Wain,et al.  Chimpanzee Reservoirs of Pandemic and Nonpandemic HIV-1 , 2006, Science.

[47]  Hui Li,et al.  Nef-Mediated Suppression of T Cell Activation Was Lost in a Lentiviral Lineage that Gave Rise to HIV-1 , 2006, Cell.

[48]  C. McArthur,et al.  HIV-1 Group N: evidence of ongoing transmission in Cameroon. , 2006, AIDS research and human retroviruses.

[49]  C. Brennan,et al.  Identification of HIV type 1 group N infections in a husband and wife in Cameroon: viral genome sequences provide evidence for horizontal transmission. , 2006, AIDS research and human retroviruses.

[50]  David Posada,et al.  ProtTest: selection of best-fit models of protein evolution , 2005, Bioinform..

[51]  C. McArthur,et al.  Identification and genomic sequence of an HIV type 1 group N isolate from Cameroon. , 2004, AIDS research and human retroviruses.

[52]  François Simon,et al.  Phylogenetic characteristics of three new HIV-1 N strains and implications for the origin of group N , 2004, AIDS.

[53]  George Banting,et al.  Bst‐2/HM1.24 Is a Raft‐Associated Apical Membrane Protein with an Unusual Topology , 2003, Traffic.

[54]  J. Kappes,et al.  Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving Fusion Inhibitor (T-20) Monotherapy , 2002, Antimicrobial Agents and Chemotherapy.

[55]  J. Kappes,et al.  Sensitivity of Human Immunodeficiency Virus Type 1 to the Fusion Inhibitor T-20 Is Modulated by Coreceptor Specificity Defined by the V3 Loop of gp120 , 2000, Journal of Virology.

[56]  K. Lole,et al.  Full-Length Human Immunodeficiency Virus Type 1 Genomes from Subtype C-Infected Seroconverters in India, with Evidence of Intersubtype Recombination , 1999, Journal of Virology.

[57]  F. Brun-Vézinet,et al.  Identification of a new human immunodeficiency virus type 1 distinct from group M and group O , 1998, Nature Medicine.

[58]  B. Chesebro,et al.  Effects of CCR5 and CD4 Cell Surface Concentrations on Infections by Macrophagetropic Isolates of Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.

[59]  D. Thomas,et al.  A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. , 1998, Molecular cell.

[60]  D. T. Jones,et al.  A new approach to protein fold recognition , 1992, Nature.